Looking at the world, focusing on innovation 2017 China Pharmaceutical R & D Innovation Summit Forum was held ceremoniously!

The pharmaceutical industry has entered a critical period of deepening reform and rapid integration For a while, "innovation", "internationalization" and "Biopharmaceutics" have become the hottest keywords in this industry "Innovation" is the brand of this era, "internationalization" is the only way for enterprises to survive in the future, "bio medicine" is a synonym for high investment and high return, the three are inseparable Only by doing well in innovation can the development of pharmaceutical industry successfully embark on the road of internationalization, and the research and development of bio innovative drugs is the biggest trend of international drug research and development Conference express experts, famous enterprises and specialized media gathered to talk about major events From September 9 to 10, 2017, under the guidance of China Pharmaceutical University, Chongqing Economic and Information Technology Commission, China Pharmaceutical Education Association, and sponsored by yaozhi.com and China Pharmacy magazine, the 2017 China Pharmaceutical Summit Forum and the release of the top 100 research and development strength of pharmaceutical enterprises started as promised More than 30 experts and scholars represented by academician Wei Yuquan, Professor Li Xiaohui and Professor Zhang Zhirong As agreed, 27 reports, 1 summit dialogue and 1 high-end technology transfer were conducted on the topics of "innovative drug research and development, cardiovascular drug research and development, drug delivery system application, new policy of drug research and development and industrial integration, drug clinical trial verification, progress analysis of generic drug consistency evaluation, the way of internationalization of Chinese pharmaceutical enterprises, and the construction and development of PIVAS connotation", attracting Nearly 500 enterprises and their representatives attended the meeting At the meeting, the 2017 ranking of China's pharmaceutical R & D strength was solemnly released, and nearly 100 enterprises represented by Zhengda Tianqing, Jiangsu Hengrui, Shanghai Fosun, Guangdong Dongguang, Yangtze River Pharmaceutical and Jiangsu Kangyuan won awards and received medals on site Many professional media and mainstream media, such as China Pharmacy magazine, medicine guide, Xinhua news agency, Chongqing daily, Chongqing Business News, Chongqing Morning News, Chongqing Evening News, Chongqing TV station, Nan'an TV station, etc., reported on the spot A brilliant part of the conference scene: leaders of the government, colleges and universities, and enterprises support innovation The distinguished guests of this conference are: academician of Chinese Academy of Sciences, director of clinical oncology center of West China Hospital and director of National Key Laboratory of Biotherapy, former vice president of Sichuan University, Professor of Sichuan University, director of Key Laboratory of Ministry of education of targeted drugs and drug delivery system, former president of Western Medicine College of China, Zhang Zhirong, deputy director of Chongqing small and Medium Enterprises Bureau, CIP model of industrial Internet Zhang Yongjun, founder, Wang Maochun, deputy secretary of the CPC Nan'an District Committee, Shaoying, vice president of Fuxing Pharmaceutical, director of R & D center and former director of CFDA drug review center, and other leaders attended the summit forum Shi Yuanping, founder and chairman of yaozhi.com, Lu Tao, vice president of China Pharmaceutical University, Xie Zhijie, director of Medicine Office of Chongqing Economic and Information Technology Commission, and LV Yi, vice president of Nan'an District People's government, delivered welcome speeches for the conference Mr Xie Zhijie, the leader of the speech, said that in recent years, the country has been accelerating the innovation and development of the pharmaceutical industry, and the Chinese pharmaceutical industry is entering a new era of innovation and globalization Following the national development pace, Chongqing attaches great importance to the development of the pharmaceutical industry, and has issued a series of supporting policies to help Chongqing and even the national pharmaceutical enterprises develop and seek welfare Professor Lu Tao said that 2016 is a year with frequent policy issues The state has increased investment in new drug research and development, accelerated the speed of new drug approval, and created a good environment for new drug research and development It is hoped that the convening of this conference can gather consensus and strength in the industry and jointly build a stronger domestic pharmaceutical R & D innovation strength In addition to the main meeting, the conference is divided into two sub venues and two groups of thematic reports on pharmacy and drug use, with rich and unusual contents Wei Yuquan, academician of the Chinese Academy of Sciences, director of the clinical oncology center of West China Hospital and director of the National Key Laboratory of Biotherapy, former vice president of Sichuan University, made a wonderful theme report entitled "innovative drug research and development and opportunities in China", academician Wei pointed out that "at present, there are good opportunities for new drug research and development in China, and the state has made a series of major reforms in drug supervision and administration at all levels The government's huge investment in policies and funds for the biomedical industry, especially the implementation of major national new drug projects, has greatly promoted the research and development of innovative drugs There are more than 900 biological drugs in clinical trials in the United States, accounting for a quarter of the total innovative research and development, and 8 of the 10 best-selling drugs in the world are biological therapy drugs " Academician Wei stressed that we should attach great importance to occupying a place in the field of international frontier biotechnology research and basic research, seize the commanding height of biological treatment and biological medicine research and development, strengthen source innovation and transform these frontier biotechnology and basic research results into products or clinical treatment means for disease treatment as soon as possible, so as to realize industrialization Nearly 20 experts and professors in the main venue of the pharmaceutical branch discussed and broken down the key points, difficulties and internationalization path of Chinese pharmaceutical R & D innovation one by one Zhang Zhirong, Professor of Sichuan University, director of the Key Laboratory of the Ministry of education of targeted drugs and drug delivery system, and former dean of Western Medicine College of China, reported on the theme of "the role of drug delivery system in new drug research and development and preparation innovation strategy" to solve the drug-forming problem of candidate drugs for enterprises through drug delivery system; Drug Research Institute of Military Medical University of the people's Liberation Army and Chongqing pharmacodynamics The theme report of "current situation, problems and solutions of cardiovascular drug research and development" by Professor Li Xiaohui, director of the evaluation center and a person of Science Chinese in 2015, reveals the drug research and development plan of cardiovascular disease, the main cause of death in the new era; the summit dialogue links 8 representatives of universities, enterprises and industry elites to stand on the height of international research and development, combining the achievements and fields of drug research and development in China , deficiency and other multi-dimensional analysis and innovation to explore how Chinese pharmaceutical enterprises enter the road of internationalization Classic reports abound, the atmosphere of the venue is solemn and dignified, and the participants have gained a lot Exhibition of experts in pharmaceutical branch With the theme of "construction and development of PIVAS connotation", the branch of pharmacy takes Wu yongpei, honorary director of Pharmaceutical Management Committee of China Hospital Association, as its theme, to promote the construction and development of PIVAS, Chen Ji, director of Pharmacy Department of the First Affiliated Hospital of Xinjiang Medical University, as its theme, and Wang Gang, Affiliated Children's Hospital of Chongqing Medical University, as its theme Nine thematic reports were conducted in the center of "characteristics of pulse medication and standard deployment of PIVAS" The construction and development of PIVAS, quality control and standard deployment of PIVAS, and characteristics of pediatric intravenous medication were explained in detail, so as to standardize clinical intravenous medication behavior and improve the level of rational clinical intravenous medication Experts in the drug branch show the classic reproduction of chemical medicine, traditional Chinese medicine and biological medicine Following the release of the 2016 China Pharmaceutical R & D strength ranking, the 2017 China Pharmaceutical R & D strength ranking (including the general list, chemical medicine list, traditional Chinese medicine list, biological medicine list and brand list) of the second pharmaceutical intelligence ranking, which has attracted the attention of the industry, was solemnly released on the site of this session Compared with the first list in 2016, in addition to the great changes in the brand list, the top ten enterprises in the general list, chemical medicine list, traditional Chinese medicine list and biological medicine list have not changed much, but the ranking ushered in a new reshuffle Zhengda Tianqing, the runner up enterprise in the 2016 general list, won two titles in the general list and chemical medicine list this year, becoming the double champion in 2017; Guangdong dongyangguang pharmaceutical industry successfully bucked the attack, jumping from 28 in the 2016 general list to the 7th in this year's general list, making remarkable progress Don't forget the original intention, forge ahead As Professor Lu Tao said, the future of China's pharmaceutical R & D innovation is in the hands of these benchmarking enterprises, which will surely become a powerful driver of the development of China's pharmaceutical industry, reshape the market shape of China's courage to innovate and dare to work hard, and lead the industry to stride forward Group photo of expert leaders at the award ceremony of the shortlisted enterprises in 2017 ranking of China's pharmaceutical R & D strength